2046 related articles for article (PubMed ID: 21450337)
21. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
22. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
23. New therapeutics for osteoporosis.
Ng KW; Martin TJ
Curr Opin Pharmacol; 2014 Jun; 16():58-63. PubMed ID: 24699340
[TBL] [Abstract][Full Text] [Related]
24. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
25. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Tankó LB
Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
[TBL] [Abstract][Full Text] [Related]
26. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
27. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
28. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
29. [Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].
Jakob F; Genest F; Baron G; Stumpf U; Rudert M; Seefried L
Unfallchirurg; 2015 Nov; 118(11):925-32. PubMed ID: 26471379
[TBL] [Abstract][Full Text] [Related]
30. Prevention and treatment of postmenopausal osteoporosis.
Tella SH; Gallagher JC
J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
[TBL] [Abstract][Full Text] [Related]
31. [Denosumab - a new option in the treatment of osteoporosis].
Franek E
Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
[TBL] [Abstract][Full Text] [Related]
32. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
33. Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Muschitz C; Fahrleitner-Pammer A; Huber J; Preisinger E; Kudlacek S; Resch H
Wien Med Wochenschr; 2012 Sep; 162(17-18):374-9. PubMed ID: 22688622
[TBL] [Abstract][Full Text] [Related]
34. Update on osteoporosis treatment.
Nogués X; Martinez-Laguna D
Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on osteoporosis therapies.
Cairoli E; Zhukouskaya VV; Eller-Vainicher C; Chiodini I
J Endocrinol Invest; 2015 Mar; 38(3):303-11. PubMed ID: 25577263
[TBL] [Abstract][Full Text] [Related]
36. Data from extension trials: denosumab and zoledronic acid.
Dore RK
Curr Osteoporos Rep; 2012 Mar; 10(1):16-21. PubMed ID: 22086442
[TBL] [Abstract][Full Text] [Related]
37. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
38. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
39. New approaches to the treatment of osteoporosis.
Silva BC; Bilezikian JP
Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170
[TBL] [Abstract][Full Text] [Related]
40. [Denosumab for treatment of postmenopausal osteoporosis].
Syversen U; Halse JI; Geisler J; Eriksen EF
Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]